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To the Editor, 42 
Eosinophilic dermatosis of hematologic malignancy (EDHM) is a non-specific skin disease primarily 43 
associated with chronic lymphocytic leukemia (CLL).1,2,3 Despite being a common disease in the 44 
hematology setting, often misdiagnosed as an exaggerated reaction to mosquito bites,2 there is a 45 
shortage of dermatology-oriented reports. Here we report on a retrospective case series of EDHM 46 
carried out in our department from November 2014 to January 2017. The main results of the study 47 
are listed in table 1. 48 
We identified 37 patients on the basis of the proposed EDHM diagnosis criteria, which include: i) 49 
known history of onco-hematological disease, ii) recurrent episodes of papules, nodules, urticarial 50 
plaques or blisters with intense pruritus, iii) eosinophilic infiltration upon histopathology, and iv) 51 
exclusion of other causes of tissue eosinophilia.1 The majority suffered from indolent B-cell 52 
disorders, primarily B-CLL (51%) and various types of B-cell non-Hodgkin lymphomas (30%), 53 
whereas acute leukemia was observed in four patients (10%). At the time of EDHM onset, only a 54 
minority of them (25%) underwent chemotherapy due to active/progressive disease. 55 
The eruption was widespread , albeit mostly occurring on the lower (90%) and upper limbs (79%). 56 
However, over half of the cases had lesions on the trunk and 25% reported painful lesions on the 57 
face, scalp, and neck. 58 
The majority of the patients presented with pruritic erythematous papules, plaques, and nodules 59 
with a smooth surface and color ranging from slightly pink to bright red, or more cyanotic hues. In 60 
one third of cases, tense blisters resembling Bullous Pemphigoid (BP) were evident, especially on 61 
the legs (Figure 1A). 62 
Skin specimens showed variably dense, mainly perivascular lymphohistiocytic and eosinophilic 63 
infiltrates in the upper and mid-dermis in the majority of cases (80%), extending to the deep 64 
dermis and subcutaneous fat in 20% of cases. In two cases, the histologic features resembled those 65 
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of Wells syndrome, revealing numerous eosinophils with flame figures in the deep dermis. Dermal-66 
epidermal detachment was observed in 10 cases, raising suspicion of BP. In these cases, direct 67 
immunofluorescence was negative. No relevant epidermal changes were found, except for 68 
spongiosis in two specimens (Figure 1B). 69 
Almost all patients showed some clinical benefit with the proposed treatment: most of the patients 70 
were treated with systemic steroids with/without concomitant topical steroids. A minority of 71 
patients achieved clinical improvement with other regimens, including doxycycline with/without 72 
nicotinamide and UVA1 phototherapy. The overall response rate was 93%. However, in many cases 73 
(63%) the response was short-lived and the patient suffered a relapse. 74 
Our study shows that EDHM potentially occurs in a wide range of hematologic cancers, with 75 
differing biological behavior and of either lymphoid or myeloid origin. Due to its 76 
clinical/pathological heterogeneity and its tendency to persist over long periods, it may represent 77 
both a diagnostic and therapeutic challenge. The overlap with BP should be kept in mind to avoid 78 
misdiagnosis and may have led to an overestimation of the BP incidence in this setting.1,4,5 Besides 79 
systemic steroids, doxycycline, nicotinamide, and UVA1 phototherapy could be effective therapeutic 80 
alternatives considering their lower long-term toxicity, but this data warrants further prospective 81 
investigations. 82 
To conclude, we believe that EDHM is an underestimated disorder. Although there is no evidence to 83 
suggest that EDHM has a negative impact on the prognosis for the underlying malignancy, it has 84 
significant negative implications for patients given its uncomfortable symptoms and chronic, 85 
relapsing course. The main limitation of this study is its retrospective design. Further 86 
pathophysiological insights and long-term prospective studies are advisable to gain a better 87 
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Table 1. Summary of the main results of the study, including demographic, clinical and therapeutic data 106 
in patients with eosinophilic dermatosis of haematological malignancies (EDHM).  107 
Characteristic Value 
Enrolled patients 37 
Male 17 (46%) 
Female 20 (54%) 
Associated malignancies 
B-cells chronic lymphocytic leukaemia 19 (51%) 
B-cells non Hodgkin lymphoma 11 (30%) 
Multiple myeloma/monoclonal gammopathy of 
undermined significance 
2 (5%) 
Acute leukemia 4 (10%) 
Aggressive T-cell lymphoma 1 (2.5) 
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Age at time of hematologic diagnosis (years) Mean = 66, range = 40-88, median = 67 
Age at time of EDHM diagnosis (years) Mean = 70, range = 41-89, median = 74 
Latency between hematological diagnosis and 
EDHM (months) 
Mean = 57, median = 40, range = 5-191 
Follow up (months) Mean = 8.7, median = 5, range = 0-34 
Previous exposure to chemotherapy 27/34 (80%) 
On chemotherapy at time of skin rash 7/34 (20%) 
Duration of rash (months) Mean = 7, median = 3.5, range = 1-34 
Seasonality 
Spring 13/37 (35%) 
Summer  10/37 (27%) 
Autumn 9/37 (24%) 
Winter 5/37 (13%) 
Involved sites 
Head/neck 9/37 (24%) 
Trunk 20/37 (54%) 
Upper limbs 30/37 (81%) 
Lower limbs 34/37 (91%) 
Type of lesions 
Papules 28/37 (75%) 
Plaques 17/37 (45%) 
Nodules 15/37 (40%) 
Vesicles  7/37 (19%) 
Blisters 12/37 (32%) 
Therapy 
Prednisolone 0.5 mg/kg/day  16/34 (46%) 
Prednisolone 1.0 mg/kg/day 8/34 (23%) 
Topical steroids 12/34 (35%) 
Oral antihistamines 6/34 (18%) 
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Cyclosporine 1/34 (3%) 
UVA1 2/34 (6%) 
Doxycicline 4/34 (12%) 
Oral nicotinamide 1g/die 4/34 (12%) 
Overall response rate 28/30 (93%) 
Complete responses 12/30 (40%) 
Partial Responses 16/30 (53%) 
No Response 2/30 (7%) 
Relapse rate 12/19 (63%) 
Mean relapse free interval (months) Mean = 5, median = 4, range = 1- 14  
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Figure legend  113 
Figure 1. A: Distinct clinical presentations of eosinophilic dermatosis of hematologic malignancy. a) 114 
light pink plaque on a leg resembling Wells Syndrome. b-c) multiple erythematous papules and 115 
nodules on the head and neck. d) tense blisters, some hemorrhagic, on the forearm. e) multiple, 116 
monomorphic, centered erythematous papules on the trunk that persisted for months. B: Distinct 117 
histopathologic presentation of eosinophilic dermatosis of hematologic malignancy. (a) Extensive 118 
intra and subepidermal edema with dermal-epidermal detachment, and an intense, perivascular, 119 
mixed inflammatory infiltrate with numerous eosinophils, extending from the upper into the 120 
reticular dermis, resembling Wells syndrome (hematoxylin and eosin, magnification 10x). At higher 121 
magnification, it becomes possible to observe flame figures, consisting of hypereosinophilic 122 
collagen fibers surrounded by degranulated eosinophil granulocytes (hematoxylin and eosin, 123 
magnification x40). (b) Dermal-epidermal unilocular detachment. Mixed-type inflammatory 124 
infiltrate with a few superficial perivascular and dermal eosinophilic granulocytes (hematoxylin 125 
and eosin, magnification x10). (c) Acanthosis and mild epidermal spongiosis. Edema of the upper 126 
dermis. Presence of a moderate, inflammatory interstitial infiltrate consisting of eosinophilic 127 
granulocytes in the upper and mid-dermis (hematoxylin and eosin, magnification x20). 128 
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